Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2, 2005. The report is a notification of changes in directors' interests in the company's Ordinary Shares rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and share ownership disclosures.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On June 1, 2005, Abacus (GSK) Trustees Limited transferred 7,042 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on June 2, 2005.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future financial performance. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—are interested in the shares held in the GSK Trust in the same manner as other employees.
Key Facts for Investor Verification
- 7,042 Ordinary Shares were transferred from the GSK Trust to employee plan participants on June 1, 2005.
- Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold indirect interests in the GSK Trust shares.
- This filing does not contain financial performance data; investors should refer to Form 20-F for comprehensive financial results.